Preclinical studies have been performed in endometrial cancer cells and one of these demonstrated, using 16 cell lines, that the PARP inhibitor Olaparib was efficient but not necessarily associated with the PTEN status of the cell line [204]. The gene discussed is PARP1; the disease is endometrial cancer.